	Telehealth platform (n = 92)	Clinic / med spa (n = 17)	Online pharmacy (n = 14)	Research-chemical (n = 17)	Compounder 503A/503B (n = 9)	API / other manufacturer (n = 5)
Unapproved new drug (505(a))	5	6	93	100	89	40
Inadequate directions for use (502(f)(1))	5	6	93	18	89	40
Prescription requirement cited (503(b))	0	0	86	6	0	0
False/misleading labeling (502(a))	100	100	7	0	22	60
False/misleading compounded-drug advertising or promotion (502(bb))	100	100	7	0	0	0
CGMP / insanitary conditions (501(a)(2)(B)/(A))	0	0	0	0	100	100
Sterility assurance	0	0	0	0	100	20
503A conditions not met	5	6	0	0	11	20
503B conditions not met	5	6	0	0	67	0
Retatrutide or other unapproved incretin	5	6	0	82	11	20
"Same as" / same active ingredient claim	71	59	7	0	0	0
"Generic" claim	12	18	7	0	0	0
Implied FDA approval claim	52	53	21	18	0	20
Firm-branded product	49	35	0	0	0	0
Use of approved brand names	66	76	57	24	0	0
"Research use" / not for human consumption	0	0	0	100	0	0
Offered without prescription	0	0	57	6	0	0

Cells: % of letters to each seller type in which FDA cited the violation (top block) or the claim/feature (bottom block).